A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers

Big Pharma Will Have $530bn To Spend

 
• By Andrew McConaghie

As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.

Pfizer
Pfizer's COVID-19 vaccine windfall will help fuel its M&A strategy over the next 5 years. • Source: Alamy

More from Deals

More from Business